We also showed that this acquisition of tumorigenicity and EMT initiated by the loss of p53 function are further promoted by the tumor microenvironment in vivo, resulting in enhanced tumorigenicity, metastatic potential, and cell motility. The gene discussed is TP53; the disease is neoplasm.